Is insulin the most effective injectable antihyperglycaemic therapy?

Diabetes, Obesity and Metabolism

Volumn 17, Issue 2, 2015, Pages 145-151

  Buse, J B ^a   Peters, A ^b   Russell Jones, D ^c   Furber, S ^d   Donsmark, M ^d   Han, J ^e   Macconell, L ^e   Maggs, D ^e   Diamant, M ^f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d NOVO NORDISK A S   (Denmark)

^e AMYLIN PHARMACEUTICALS INC   (United States)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Basal insulin; Exenatide; GLP 1 receptor agonists; HbA1c; Liraglutide

Indexed keywords

EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLARGINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LONG ACTING INSULIN; PEPTIDE; VENOM;

ADULT; ARTICLE; BODY WEIGHT; DRUG EFFICACY; DRUG SAFETY; FASTING GLUCOSE LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT GAIN; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; VENOMS;

EID: 84921381285     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12402     Document Type: Article

References (12)

1. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
2. Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
3. Russell-Jones D, Vaag A, Schmitz O et al., Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
4. Qu Y. Issues for stratified randomization based on a factor derived from a continuous baseline variable. Pharm Statist 2011; 10: 232-235.
5. Handelsman Y, Mechanick JI, Blonde L et al. AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17(Suppl. 2): 1-53.
6. Goldenberg R. Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. Curr Med Res Opin 2014; 30: 431-445.
7. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014; DOI: 10.1016/S0140-6736(14)61335-0.
8. Yki-Järvinen H, Juurinen L, Alvarsson M et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007; 30: 1364-1369.
9. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51: 408-416.
10. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
11. Riddle M, Vlajnic A, Zhou R, Rosenstock J. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab 2013; 15: 819-825.
12. Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (EAGLE). Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT01117350. Accessed 22 September 2014.